tbuckley/cabot-search huggingface dataset:
Abstract 18612: Intravenous Infusion of Ultrashort-acting Beta-blocker, Landiolol, for Prevention of Immediate Recurrence of Atrial Fibrillation after Catheter Ablation
Authors: Daisuke Ishigaki, Takanori Arimoto, Tadateru Iwayama, Yoshinori Yashiro, Daisuke Kutsuzawa, Harutoshi Tamura, Satoshi Nishiyama, Hiroki Takahashi, Tetsuro Shishido, Takehiko Miyashita, Takuya Miyamoto, Joji Nitobe, Hiroshi Aoyama, Tetsu Watanabe, Isao Kubota
Journal: Circulation (2012)

BACKGROUND: Immediate recurrence of atrial fibrillation (AF) after catheter ablation (CA) troubles with patients. We investigated whether intraveneous infusion of landiolol, an ultrashort-acting beta-blocker, could inhibit immediate AF recurrence after CA by randomized controlled trial. METHOD: atients with drug-resistant AF treated by CA were assigned to receive either landiolol or placebo after the procedure. In the landiolol group, landiolol was infused ntraveneously at speed of 1 μg/kg/min and continued for 3 days after the CA. The primary end point was occurrence/non-occurrence of AF, defined as supra-ventricular arrhythmia more than 5 min, up to 3-day after CA. Logistic regression analysis was performed to investigate risk factor. RESULT: 31 and 24 patients were assigned to landiolol group and placebo group, respectively. There were no significant difference between both groups in systolic blood pressure (SBP) before CA, diastolic blood pressure (DBP) before CA and changes from pre-CA to post-CA of SBP and DBP. AF recurrence occurred in 5 patients (10%) in landiolol group versus 11 patients (45%) in the placebo group (P=0.016, Figure). Multivariable analysis revealed that landiolol infusion significantly reduced the risk of transient AF recurrence after procedure (Hazard ratio: 0.208, 95% confidence interval of hazard ratio: 0.048-0.897, P=0.035). CONCLUSIONS: Short-term landiolol infusion successfully decreased immediate AF recurrence after CA without changing SBP and DBP. Administration of landiolol may become a new strategy to facilitate management after CA.
Abstract 14753: Prognostic Value of TAPSE in Critically Ill Patients
Authors: Harish Raj Seetha Rammohan, Shiva Ponamgi, Abel Romero-Corral, Kinnari Murthy, Bhaskar Purushottam, Vincent M Figueredo, Gregg S Pressman
Journal: Circulation (2013)

Background: Transient left ventricular dysfunction (e.g. Takotsubo cardiomyopathy) can occur under conditions of extreme emotional or physiological stress. There is little data on right ventricular...
포스터전시 : 간이식 환자에서 하장간막 동정맥류와 문맥협착에 의한 허 혈걸 대장염
Authors: In Hee Kim, Seok Lee, Young Gyun Na, Yoon Jae Lee, Yu Jeong Hwang, Seong Hun Kim, Seung Ok Lee, Soo Teik Lee, Dae Ghon Kim
Journal: Clinical and Molecular Hepatology (2008)
The Synergistic Effects of Matrix Stiffness and Composition on the Response of Chondroprogenitor Cells in a 3D Precondensation Microenvironment
Authors: Bita Carrion, Mohammad F. Souzanchi, Victor T. Wang, Gopinath Tiruchinapally, Ariella Shikanov, Andrew J. Putnam, Rhima M. Coleman
Journal: Advanced Healthcare Materials (2016)

Improve functional quality of cartilage tissue engineered from stem cells requires a better understanding of the functional evolution of native cartilage tissue. Therefore, a biosynthetic hydrogel was developed containing RGD, hyaluronic acid and/or type-I collagen conjugated to poly(ethylene glycol) acrylate to recapitulate the precondensation microenvironment of the developing limb. Conjugation of any combination of the three ligands did not alter the shear moduli or diffusion properties of the PEG hydrogels; thus, the influence of ligand composition on chondrogenesis could be investigated in the context of varying matrix stiffness. Gene expression of ligand receptors (CD44 and the b1-integrin) as well as markers of condensation (cell clustering and N-cadherin gene expression) and chondrogenesis (Col2a1 gene expression and sGAG production) by chondroprogenitor cells in this system were modulated by both matrix stiffness and ligand composition, with the highest gene expression occurring in softer hydrogels containing all three ligands. Cell proliferation in these 3D matrices for 7 d prior to chondrogenic induction increased the rate of sGAG production in a stiffness-dependent manner. This biosynthetic hydrogel supports the features of early limb-bud condensation and chondrogenesis and is a novel platform in which the influence of the matrix physicochemical properties on these processes can be elucidated.
Efficacy of combined docetaxel and bevacizumab treatment in hormone-refractory metastatic prostate cancer pretreated with docetaxel: A single institution experience.
Authors: A. Sangal, F. Gulmi, H. Kim, U. Mooppan, Y. Gu, R. Saini, B. Sharma, N. Guttierez, J. C. Wang
Journal: Journal of Clinical Oncology (2010)

e15150 Background: Although taxanes represent the most active agents for the first-line treatment of metastatic hormone-refractory prostate cancer (HRPC), most patients eventually progress while receiving taxane-based treatments. No agents are currently approved for second-line therapy in HRPC. Methods: Seven patients with HRPC, pre-treated with docetaxel received combination therapy with bevacizumab (15 mg/kg) and docetaxel (60 mg/m2) every 3 weeks. The inclusion criteria were: age >18 years, World Health Organization performance status 0-1, histologically confirmed adenocarcinoma of prostate, metastatic disease shown by either CT scan or bone scan, previous hormonal therapy with LHRH and anti-androgen combined and progression on chemotherapy with docetaxel as first line treatment. Progression was defined as >50% increase in PSA on two determinations in two weeks apart. The response criteria is defined as with measurement of PSA on two separate occasions with two weeks apart as follows: 1) major PSA response was defined as a reduction from baseline of ≥50%, 2) minor response was defined as a ≥25% to 49%, 3) stable disease defined as to a <25% PSA response, 4) progression defined as more than 25% increase. Results: The study was carried out from July 2006 till Dec 2009. The mean age of our patients was 72.3 years (range 51-82 years). The mean duration of combination treatment was 5.4 months (range 2-9 months). Three patients (43%) had major PSA response; three patients (43%) had minor PSA response while one patient (14%) had disease progression on combination therapy. Two partial responders had thrombocytopenia due to which the treatment was discontinued and two patients experienced grade 1-2 anorexia. No evidence of headaches, proteinuria, hematuria or bleeding was observed. Conclusions: Our results show that the combination of bevacizumab and docetaxel is an active regimen in HRPC after failure on treatment with docetaxel. Platelet counts should be monitored during the therapy. These promising results may provide a basis for further research in a large multicenter trial. No significant financial relationships to disclose.
Recovery From Liquid-Nitrogen Temperature of Established Cell Lines Frozen in Chemically Defined Medium
Authors: Virginia J. Evans, Hector Montes de Oca, Jay C. Bryant, Edward L. Schilling, John E. Shannon
Journal: JNCI Journal of the National Cancer Institute (1962)

Human skin epithelium (NCTC 3075), monkey kidney epithelium (NCTC 3526-LLCMK2), and Earle's strain L C3H mouse fibrosarcoma cells (NCTC 2071), cultured in chemically defined medium NCTC 109 with no added proteins for 2 to 6 years, were frozen to −196° C in this medium after incorporation of 6 or 12 percent glycerol. The cells were subsequently thawed and cultured in this medium with no apparent alterations. A slow rate of freezing, 1° to 2° C per minute in a dry-ice ethanol bath, was used until −25°C was reached. Then the ampoules of frozen cell suspension were plunged into liquid nitrogen for storage. The cells were thawed within 1 minute or less by immersion and agitation of the ampoules in water at 40° C. The human skin and monkey kidney strains were capable of proliferation, provided the concentration of glycerol was reduced to no more than 1 percent in the cell suspension by dilution with medium NCTC 109 after the thawing. NCTC 2071 cells could be recovered after freezing with 12 percent glycerol only when the glycerol was removed in gradients of 1 percent with 3 to 4 minutes allowed between each gradient until less than 1 percent remained in the cell suspension. They could, however, proliferate when recovered from medium NCTC 109 and 6 percent glycerol, irrespective of the rate of glycerol removal. These data show that NCTC 2071 (strain L) cells are more sensitive to the manipulations required in freezing procedures than the other two lines of cells. With appropriate modifications in existing freezing procedures, the recovery of cells in chemically defined medium is possible. Further studies on the long-term preservation of these and other cell lines in liquid nitrogen are in progress.
Treatment Recommendations for Patients With a Diagnosis of Ductal Carcinoma In Situ
Authors: Niels Keiding, Signe Opdahl, Lars Holmberg
Journal: JAMA Oncology (2016)

To the Editor The large register study by Narod et al1 reported breast cancer–specific mortality after a ductal carcinoma in situ (DCIS) diagnosis with special focus on the influence of initial treatment received. There are 2 methodological problems with this article.
Induction of Duodenal Tumors in F344 Rats by Continuous Oral Administration of &lt;italic&gt;N&lt;/italic&gt;-Ethyl-&lt;italic&gt;N&lt;/italic&gt;-nitrosourea&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: M Takeuchi, T Ogiu, M Nakadate, S Odashima
Journal: JNCI Journal of the National Cancer Institute (1980)

Forty male and 40 female inbred F344 rats were given a solution of 400 mg N-ethyl-N-nitrosourea/liter in their drinking water. Digestive tract tumors were induced in 32 males (an incidence rate of 80%) and in 28 females (an incidence rate of 70%). Among these digestive tract neoplasms, duodenal tumors occurred most frequently. Most were of the epithelial type, such as adenoma or adenocarcinoma. Tumors in hematopoletic organs were also found in 15 males (38% incidence) and in 17 females (43% incidence).
A phase I MMRC clinical trial testing the combination of bortezomib and tipifarnib in relapsed/refractory multiple myeloma
Authors: S. Lonial, D. Francis, C. Karanes, S. Trudel, A. Dollard, D. Harvey, J. Kaufman
Journal: Journal of Clinical Oncology (2009)

8597 Background: Preclinical work from our group has demonstrated that the combination of a farnesyl transferase inhibitor and bortezomib results in enhanced plasma cell apoptosis, and more recently, we have suggested that the mechanism for this synergy is due to inhibition of HDAC6, and inhibition of the proteasome and aggresome pathway. Methods: Patients with relapsed or refractory myeloma were treated with bortezomib at 1.0 or 1.3 mg/m2 on a standard schedule in conjunction with escalating doses of tipifarnib (100–400mg/BID) given on days 2–15 every 21 days. Dose escalation was accomplished using an adaptive phase I design (Escalation With Overdose Control). Results: 22 patients have been enrolled, of which 18 are evaluable, into respective tipifarnib dose levels 100 mg (n=6), 200mg (n=5) and 300mg (n=5) and 400mg (n=2). Median age for the enrolled patients is 59 and median time from myeloma diagnosis was 4.7 years. The average number of prior therapies was 4.5. Among these patients with advanced myeloma and refractory disease, stabilization of disease or better was seen among 8/10 patients with 2 of the 8 achieving an MR. Among the patients achieving clinical benefit, 1 patient had a stable M-protein, but experienced an 80% reduction in circulating plasma cells while on therapy, and another has had a 75% reduction in the free light chain assay. The most common drug related side effect was was Gr2 diarrhea (23.5%). Hematologic toxicities were difficult to ascertain as patients had advanced myeloma and many were entered onto study with platelet counts between 25 and 50. Additional grade 3 toxicities included renal insufficiency (related to PD), pneumonia and altered mental status which were all considered not related to study drug but to progression of disease. There were no Grade 3-5 drug related toxicities. One patient experienced grade 2 peripheral neuropathy who did not have pre existing PN at baseline. Conclusions: The combination of bortezomib and tipifarnib is supported by preclinical rationale and has produced stable disease or better among 10 of 18 patients with refractory myeloma. Optimal dose of tipifarnib and bortezomib have yet to be defined, and additional patients are being enrolled with 1.3mg/m2 of bortezomib, and escalating doses of tipifarnib. [Table: see text]
Impact of E27X cdkn2a mutation on p16 and p14arf expression in melanoma families and pancreatic cancer
Authors: P. Queirolo, P. Ghiorzo, S. Gargiulo, S. Gliori, M. Acquati, M. Boitano, G. Bodini, V. Segalla, V. Pugliese, G. Fornarini, G. Bianchi Scarrà
Journal: Journal of Clinical Oncology (2007)

10543 Background: Mutations in the CDKN2A gene underlie melanoma susceptibility in as many as 50% of melanoma kindreds in selected populations, and several CDKN2A founder mutations have been described. Inherited mutations in CDKN2A have been found to be associated with other non-melanoma cancers including pancreatic cancer and neural system tumours. Here we report a novel germline mutation in exon 1 of the CDKN2A gene, E27X, which we first detected in melanoma patients living in or originally from a small geographic area bordering Liguria, in north-western Italy. A subset of melanoma kindreds positive for this mutation displayed pancreatic cancer and neuroblastoma. Methods: We investigated 70 pancreatic cancer patients from a case-control study living in or originally coming from a small geographic area bordering Liguria, in north-western Italy, for CDKN2A mutations and ARF. Results: 2 out of 70 patients displayed the E27X mutation and 1 of the 2 patients had a first degree relative affected by pancreatic cancer. Conclusions: E27X generates a premature stop codon, leading to dramatically reduced protein levels of p16 and leaving p14ARF unaltered. As pancreatic cancer and neural system tumours have been postulated to be preferentially associated with CDKN2A mutations located in exon 2 and/or affecting p14ARF alone, the position of E27X in exon 1a provides interesting insights towards clarifying the mechanisms by which the CDKN2A/ARF locus is involved in cancer predisposition. Its finding in pancreatic cancer patients confirms common susceptibility to melanoma and pancreatic cancer due to this CDKN2A exon 1 mutation. No significant financial relationships to disclose.
The usefulness of measuring tear periostin for the diagnosis and management of ocular allergic diseases
Authors: Hiroshi Fujishima, Naoko Okada, Kenji Matsumoto, Kazumi Fukagawa, Ayako Igarashi, Akio Matsuda, Junya Ono, Shoichiro Ohta, Hideki Mukai, Mamoru Yoshikawa, Kenji Izuhara
Journal: Journal of Allergy and Clinical Immunology (2016)
Severe Coronary Vasculitis During a Systemic Lupus Erythematosus Flare Improved Angiographically With Immune-Suppressant Therapy
Authors: Tina Saparia, Robert J. Lundstrom
Journal: Circulation (2016)

A 47-year-old woman with systemic lupus erythematosus with nephritis, maintained on prednisone, experienced transient chest pain radiating to her left arm and shoulder.She was hospitalized for a potassium level of 6.1 mEq/dL.She lost consciousness after receiving sodium polystyrene enemas.Cardiopulmonary resuscitation was performed briefly.Her troponin-I was 16 ng/mL, and echocardiography revealed inferior, posterior-lateral, and apical hypokinesia; normal chamber sizes; and moderate mitral regurgitation.Coronary angiography revealed multiple small saccular aneurysms scattered along the smaller epicardial arteries and occlusion in the distal obtuse marginal branch (Figure , A andB).Hemodynamics of the right side of the heart were normal.Left ventriculography demonstrated moderate mitral regurgitation and ventricular dilatation with anterior, apical, and inferior hypokinesis.She received intravenous methylprednisolone and cyclophosphamide.Fifteen months later, she had severe mitral regurgitation with worsening left ventricular function.Coronary angiography before mitral valve repair showed complete resolution of the coronary aneurysms and only mild diffuse luminal irregularities of the coronary arteries (Figure, C and D).Valve repair was uneventful, with subsequent improvement in left ventricular function and resolution of mitral regurgitation.
Deficiency of sorting nexin 10 prevents bone erosion in collagen-induced mouse arthritis through promoting NFATc1 degradation
Authors: Chun Zhou, Yan You, Weixing Shen, Yi-Zhun Zhu, Jing Peng, Hao-Tian Feng, Ying Wang, Dong Li, Wei-Wei Shao, Cui-Xian Li, Wan-Zhen Li, Jiake Xu, Xiaoyan Shen
Journal: Annals of the Rheumatic Diseases (2015)

Objective Periarticular and subchondral bone erosion in rheumatoid arthritis caused by osteoclast differentiation and activation is a critical index for diagnosis, therapy and monitoring of the disease. Sorting nexin (SNX) 10, a member of the SNX family which functions in regulation of endosomal sorting, has been implicated to play an important clinical role in malignant osteopetrosis. Here we studied the roles and precise mechanisms of SNX10 in the bone destruction of collagen-induced arthritis (CIA) mice. Methods The role of SNX10 in bone destruction was evaluated by a CIA mice model which was induced in male SNX10 −/− mice and wild type littermates. The mechanism was explored in osteoclasts induced by receptor activator of nuclear factor κB ligand from bone marrow mononuclear cells of wild type and SNX10 −/− mice. Results SNX10 knockout prevented bone loss and joint destruction in CIA mice with reduced serum levels of TNF-α, interleukin 1β and anticollagen IgG 2α antibody. SNX10 deficiency did not block osteoclastogenesis, but significantly impaired osteoclast maturation and bone-resorption function by disturbing the formation of actin belt. The production of TRAP, CtsK and MMP9 in SNX10 −/− osteoclasts was significantly inhibited, and partially restored by SNX10 overexpression. We further demonstrated that the degradation of NFATc1 was accelerated in SNX10 −/− osteoclasts causing an inhibition of integrin β3-Src-PYK2 signalling. Conclusions Our study discloses a crucial role and novel mechanism for SNX10 in osteoclast function, and provides evidence for SNX10 as a promising novel therapeutic target for suppression of immune inflammation and bone erosion in rheumatoid arthritis.
The Burden of Inbox Notifications in Commercial Electronic Health Records
Authors: Daniel R. Murphy, Ashley N. D. Meyer, Elise Russo, Dean F. Sittig, Li Wei, Hardeep Singh
Journal: JAMA Internal Medicine (2016)

The Burden of Inbox Notifications in Commercial Electronic Health RecordsWith wider use of electronic health records (EHRs), physicians increasingly receive notifications via EHR-based inboxes (eg, Epic's In-Basket and General Electric Centricity's Documents).Examples of types of notifications include test results, responses to referrals, requests for medication refills, and messages from physicians and other health care professionals. 1,24][5][6] Information overload is of emerging concern because new types of notifications and "FYI" (for your information) messages can be easily created in the EHR (vs in a paper-based system).Furthermore, the additional workload to read and process these messages remains uncompensated in an environment of reduced reimbursements for office-based care. 1,2,4Conversely, EHRs make it easier to measure the amount of information received.We quantified the notifications that physicians received via inboxes of commercial EHRs to estimate their burden.
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
Authors: F. Stephen Hodi, Wen-Jen Hwu, Richard Kefford, Jeffrey S. Weber, Adil Daud, Omid Hamid, Amita Patnaik, Antoni Ribas, Caroline Robert, Tara C. Gangadhar, Anthony M. Joshua, Peter Hersey, Roxana Dronca, Richard Joseph, Darcy Hille, Dahai Xue, Xiaoyun Nicole Li, S. Peter Kang, Scot Ebbinghaus, Andrea Perrone, Jedd D. Wolchok
Journal: Journal of Clinical Oncology (2016)

We evaluated atypical response patterns and the relationship between overall survival and best overall response measured per immune-related response criteria (irRC) and Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) in patients with advanced melanoma treated with pembrolizumab in the phase Ib KEYNOTE-001 study (clinical trial information: NCT01295827).Patients received pembrolizumab 2 or 10 mg/kg every 2 weeks or every 3 weeks. Atypical responses were identified by using centrally assessed irRC data in patients with ≥ 28 weeks of imaging. Pseudoprogression was defined as ≥ 25% increase in tumor burden at week 12 (early) or any assessment after week 12 (delayed) that was not confirmed as progressive disease at next assessment. Response was assessed centrally per irRC and RECIST v1.1.Of the 655 patients with melanoma enrolled, 327 had ≥ 28 weeks of imaging follow-up. Twenty-four (7%) of these 327 patients had atypical responses (15 [5%] with early pseudoprogression and nine [3%] with delayed pseudoprogression). Of the 592 patients who survived ≥ 12 weeks, 84 (14%) experienced progressive disease per RECIST v1.1 but nonprogressive disease per irRC. Two-year overall survival rates were 77.6% in patients with nonprogressive disease per both criteria (n = 331), 37.5% in patients with progressive disease per RECIST v1.1 but nonprogressive disease per irRC (n = 84), and 17.3% in patients with progressive disease per both criteria (n = 177).Atypical responses were observed in patients with melanoma treated with pembrolizumab. Based on survival analysis, conventional RECIST might underestimate the benefit of pembrolizumab in approximately 15% of patients; modified criteria that permit treatment beyond initial progression per RECIST v1.1 might prevent premature cessation of treatment.
Massive duodenal variceal bleed: endoscopic ultrasonography of ruptured varix and successful endoscopic clipping treatment
Authors: Isabelle Lienhart, Adriane Lesne, Eduardo Couchonnal, Jérôme Rivory, Leonardo Sosa-Valencia, Thierry Ponchon, Mathieu Pioche
Journal: Endoscopy (2016)

Duodenal varices are a rare cause of upper gastrointestinal (GI) bleeding [1] [2] [3] [4] [5] and endoscopic management is not standardized [1] [2].
Non‐adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from <scp>SHIFT</scp>
Authors: Michael Böhm, Suzanne M. Lloyd, Ian Ford, Jeffrey S. Borer, Sebastian Ewen, Ulrich Laufs, Felix Mahfoud, Jose Lopez‐Sendon, Piotr Ponikowski, Luigi Tavazzi, Karl Swedberg, Michel Komajda
Journal: European Journal of Heart Failure (2016)
CAESAR: a new tool to assess relatives’ experience of dying and death in the ICU
Authors: Nancy Kentish-Barnes, Valérie Seegers, Stéphane Legriel, Alain Cariou, Samir Jaber, Jean-Yves Lefrant, Bernard Floccard, Anne Renault, Isabelle Vinatier, Armelle Mathonnet, Danielle Reuter, Olivier Guisset, Christophe Cracco, Amélie Seguin, Jacques Durand-Gasselin, Béatrice Éon, Marina Thirion, Jean-Philippe Rigaud, Bénédicte Philippon-Jouve, Laurent Argaud, Renaud Chouquer, Mélanie Adda, Laurent Papazian, Céline Dedrie, Hugues Georges, Eddy Lebas, Nathalie Rolin, Pierre-Edouard Bollaert, Lucien Lecuyer, Gérald Viquesnel, Marc Léone, Ludivine Chalumeau-Lemoine, Zoé Cohen-Solal, Maité Garrouste-Orgeas, Fabienne Tamion, Bruno Falissard, Sylvie Chevret, Elie Azoulay
Journal: Intensive Care Medicine (2016)